Abstract Background Anakinra, an interleukin 1β recombinant receptor antagonist, could be used to reduce corticosteroid-dosage in colchicine-resistant pericarditis. Recently anakinra has been approved treat patients presenting covid-19 related pneumonia requiring supplementary oxygen at risk of developing ARDS (identified by the finding sieric suPAR least 6 ng/mL.) Clinical case A 86-years-old ...

Abstract Background Prediction of ovarian response prior to the stimulation cycle is useful in determining optimal starting dose recombinant follicle-stimulating hormone (r-FSH). This study was designed (I) evaluate which following parameters (age, AMH, and FSH) can be used as a predictor GnRH antagonist protocol, (II) determine cutoff value AMH age for predicting poor high response, (III) inve...

A two-year-old girl with fever, diarrhea and vomiting was presented to the Emergency Department (ED). maculopapular rash on face, cervical lymphadenopathy 1st degree dehydration were being noted. Laboratory results showed leukocytosis, neutrophilia a high level of C-reactive protein (CRP). Amoxicillin prescribed, but patient’s state did not improve. She returned ED all over her body 2nd dehydra...

Whether recombinant gonadotrophin products do, indeed, represent progress for routine ovulation induction and IVF cycles, in comparison with urinary products, has remained controversial. Here we review published data with regard to respective risks, outcomes and cost for both medication options. Safety considerations favour recombinant products, while overall outcome and cost considerations fav...

PURPOSE OF REVIEW Recombinant factor VIIa has been increasingly used to provide hemostasis in nonapproved indications. This trend has resulted in concerns about safety, efficacy and costs. RECENT FINDINGS Recombinant factor VIIa seems to have hemostatic effects in posttrauma and perisurgery excessive bleeding, although further studies are required. Recombinant factor VIIa may be used to rever...

This study was performed to analyze retrospectively outcomes of stimulated in vitro fertilization (IVF) cycles where the gonadotropin-releasing hormone (GnRH) antagonist was omitted on ovulation triggering day. A total of 92 consecutive IVF cycles were included in 65 women who are undergoing ovarian stimulation with recombinant FSH. A GnRH antagonist, cetrorelix 0.25 mg/day, was started when le...